Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
Temozolomide is an oral alkylating agent that is used as the first line treatment for glioblastoma multiform, and in recurrent anaplastic astrocytoma, as well as having demonstrable activity in patients with metastatic melanoma. However, as the case with other chemotherapeutic agents, the developmen...
Main Authors: | Ahmed M. Elshazly, David A. Gewirtz |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/4/535 |
Similar Items
-
Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
by: Young Keun Hwang, et al.
Published: (2024-08-01) -
The Cytoprotective, Cytotoxic and Nonprotective Functional Forms of Autophagy Induced by Microtubule Poisons in Tumor Cells—Implications for Autophagy Modulation as a Therapeutic Strategy
by: Jingwen Xu, et al.
Published: (2022-07-01) -
The Switch between Protective and Nonprotective Autophagy; Implications for Autophagy Inhibition as a Therapeutic Strategy in Cancer
by: David A. Gewirtz
Published: (2020-01-01) -
The Cytoprotective and Cytotoxic Functions of Autophagy in Response to mTOR Inhibitors
by: Ahmed M. Elshazly, et al.
Published: (2024-06-01) -
Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protective
by: Ahmed M. Elshazly, et al.
Published: (2023-12-01)